NCT01656525 - A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

June 30, 2014

Conditions

Alzheimer's Disease

Interventions

DRUG

Gantenerumab

75 mg subcutaneous doses every 4 weeks for 24 weeks

DRUG

Gantenerumab

105 mg subcutaneous doses every 4 weeks for 24 weeks

DRUG

Gantenerumab

225 mg subcutaneous doses every 4 weeks for 24 weeks

DRUG

Placebo

subcutaneous doses every 4 weeks for 24 weeks

Trial Locations (5)

Kansai region, Kansai

Kanto region,, Kanto

Kyushu region, Kyushu

Tokai region, Toakai

Tohoku region, Tōhoku